Why do studies use composite endpoints? Why not just use OS, or which ever one clinical endpoint they want to study?
Unrelated:
In general, I'm not sure what to think about non fatal MI. The definition of MI seems to have been inconsistent over the years. I would assume most patients care about avoiding acute coronary syndrome, rather than nonfatal MI which tbh I'm not sure what that means.
My cardiologist does not recommend statins for me even though my dad died of a heart attack at 53 and my cholesterol is 250. She referred me to the following editorial. Who should I believe?
Statins for Primary Cardiovascular Disease Prevention: Time to Curb Our Enthusiasm – 2022 JAMA Internal Medicine Editorial
This editorial discussed the USPSTF's 2022 recommendation (largely unchanged from 2016) on the use of statins for primary prevention of cardiovascular disease. There continues to be concerns around the recommendation statement and the limitations in the clinical research considered by the USPSTF, including the arbitrary cutoff points used to risk-stratify patients in trials, the lack of patient-level data, and the lack of focus on clinically-meaningful outcomes. The editorial encourages a prioritization of lifestyle counseling over the marginal and uncertain benefits of statins.
It is a conversation I have all the time. In the primary prevention situation, a patient at mid-risk, (ASCVD ~ 7.5-12.5%) taking a statin will lower risk some but is unlikely to effect any one specific patient. That said, statins are generally super safe and well-tolerated. Totally gets down to the patients treatment philosophy: less is more, or let me do everything I can...
General Q:
Why do studies use composite endpoints? Why not just use OS, or which ever one clinical endpoint they want to study?
Unrelated:
In general, I'm not sure what to think about non fatal MI. The definition of MI seems to have been inconsistent over the years. I would assume most patients care about avoiding acute coronary syndrome, rather than nonfatal MI which tbh I'm not sure what that means.
Is it possible to get the raw data and see what the results were for the non smokers in the study
My cardiologist does not recommend statins for me even though my dad died of a heart attack at 53 and my cholesterol is 250. She referred me to the following editorial. Who should I believe?
Statins for Primary Cardiovascular Disease Prevention: Time to Curb Our Enthusiasm – 2022 JAMA Internal Medicine Editorial
https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2795661
This editorial discussed the USPSTF's 2022 recommendation (largely unchanged from 2016) on the use of statins for primary prevention of cardiovascular disease. There continues to be concerns around the recommendation statement and the limitations in the clinical research considered by the USPSTF, including the arbitrary cutoff points used to risk-stratify patients in trials, the lack of patient-level data, and the lack of focus on clinically-meaningful outcomes. The editorial encourages a prioritization of lifestyle counseling over the marginal and uncertain benefits of statins.
It is a conversation I have all the time. In the primary prevention situation, a patient at mid-risk, (ASCVD ~ 7.5-12.5%) taking a statin will lower risk some but is unlikely to effect any one specific patient. That said, statins are generally super safe and well-tolerated. Totally gets down to the patients treatment philosophy: less is more, or let me do everything I can...
Thanks so much for your thoughtful response!
So what are we to conclude? That yes, everyone should be on statins?
God no....